Pharmabiz5 天
Oncorena receives US FDA approval to initiate studies in US
Oncorena, a Swedish pharma company, announced that the US FDA has approved the company’s IND application to initiate the phase I/II study Oncorella-1: A phase 1/2, open label, single arm study on ...
Morningstar7 天
Oncorena receives FDA approval to initiate studies in the US
ONC175 is an investigational drug product under development that contains synthetically produced orellanine as active ingredient. Orellanine is highly specific to the kidney and induces ...
Oncorena receives FDA approval to initiate studies in the US
Oncorena is pleased to announce that the FDA has approved the Company's IND application to initiate the Phase I/II study Oncorella-1: A Phase 1/2, open label, single arm study on safety, tolerability ...
PharmiWeb7 天
Oncorena receives FDA approval to initiate studies in the US
Lund, Sweden, March 18, 2025 - Oncorena is pleased to announce that the FDA has approved the Company’s IND application to initiate the Phase I/II study Oncorella-1: A Phase 1/2, open label, single arm ...